Search Results
Dec 18, 2025, 06:59 ET Viatris Provides Pipeline Update on Four Regulatory Milestones
has cleared the Company's Investigational New Drug (IND) application for MR-146, an Enriched Tear FilmTM (ETF) Adeno-Associated Virus (AAV) gene therapy candidate targeted to treat people with neurotrophic keratopathy (NK). The Company plans to initiate a Phase 1 / 2 clinical trial, CORVITA,
More news about: Viatris Inc.
Dec 18, 2025, 02:00 ET New Data from SkylineDx Demonstrates Merlin CP-GEP Test's Superior Melanoma Risk Stratification
decision-making and reduce both under- and overtreatment in early-stage melanoma. The Merlin CP-GEP Test, validated in the largest prospective gene expression profiling study in melanoma (MERLIN_001), demonstrated
More news about: SkylineDx
Dec 17, 2025, 16:01 ET Insmed Provides Clinical and Business Update
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Dec 17, 2025, 10:00 ET GB Connections Strengthens Technical Support and Customer Service Capabilities With Two Key Appointments
Robert L. Kovar, P.E., President and CEO and build on the strong foundation of service and technical excellence established under the leadership of Gene Mannella, P.E., who continues to support the company in his role as Chairman and Executive Technology Officer.For more than 45 years, GB Connections
More news about: GB Connections LLC
Dec 17, 2025, 09:00 ET Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
of and differentiation of influenza A, influenza B, and SARS-CoV-2, the virus that causes COVID-19. The test's Co-Primers target a region on the MP gene of influenza A, whereas the mutations associated with subclade K occur in the HA region of the genome. The in silico analysis concluded that there is
More news about: Co-Diagnostics
Dec 17, 2025, 08:30 ET Xtalks Releases 2025 Webinar Year-in-Review Showcasing Key Life Science Trends
expectations and a more mature approach to deploying AI in life sciences.Cell, Gene and RNA Therapies Continue to ScaleAdvanced therapeutic modalities remained a major focus in 2025, with webinars examining cell and gene therapy clinical development and safety, as well as RNA therapeutics, including
More news about: Xtalks
Dec 17, 2025, 08:00 ET MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
accelerate clinical development and help bring differentiated solutions to patients with obesity," said Min-Jeong Shin, CEO of MEDI&GENE.Founded in 2021, MEDI&GENE has established a discovery engine centered on metabolic and obesity-related pathways and has identified multiple innovative
More news about: MEDI&GENE
Dec 17, 2025, 07:57 ET Former Michigan Sheriff, Gene Wriggelsworth, releases "50 Years of Duty," A Memoir of his Compelling Journey from Michigan State Trooper to Ingham County Sheriff
LANSING, Mich., Dec. 17, 2025 /PRNewswire/ -- Retired Ingham County Sheriff, Gene Wriggelsworth, announces the publication of his extraordinary memoir entitled 50 Years of Duty: One Police Officer's Compelling Journey from
More news about: Gene Wriggelsworth
Dec 17, 2025, 07:00 ET Bioptimus Unveils M-Optimus, a World Model for Biology
determine which patients are most likely to respond, potentially eliminating years and millions of dollars in trial costs.Predicting gene expression, treatment responses, and clinical outcomes directly from histology or multimodal data. Optimizing the use of precious clinical samples
More news about: Bioptimus
Dec 17, 2025, 07:00 ET Bioptimus Unveils M-Optimus, a World Model for Biology
determine which patients are most likely to respond, potentially eliminating years and millions of dollars in trial costs.Predicting gene expression, treatment responses, and clinical outcomes directly from histology or multimodal data. Optimizing the use of precious clinical samples
More news about: Bioptimus
Dec 17, 2025, 03:30 ET Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
single forum, enabling stakeholders to address adoption bottlenecks in deploying advanced 3D cell culture technologies for developing mAbs, cell & gene therapies, and other next-generation bio-better modalities.Biologics X 3DCC 2026 will further enable the much-needed cross-sector dialogue and
More news about: Mumbai Biocluster
Dec 17, 2025, 03:26 ET Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
single forum, enabling stakeholders to address adoption bottlenecks in deploying advanced 3D cell culture technologies for developing mAbs, cell & gene therapies, and other next-generation bio-better modalities.Biologics X 3DCC 2026 will further enable the much-needed cross-sector dialogue and
More news about: Mumbai Biocluster
Dec 16, 2025, 20:53 ET QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 16, 2025, 17:05 ET The Next Chapter in Obesity Therapeutics: Vial's INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy
SUMMARYVial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin ELeading key opinion leaders (KOLs) Drs. Jason Fung, Scott Kahan, Lawrence Cheskin, and Lee Kaplan
More news about: Vial
Dec 16, 2025, 11:53 ET Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
organizations capturing 67.5% market share as the industry transitions from boutique R&D operations to scalable bioprocessing infrastructure[1]. Gene and CAR-T therapy demand has driven CDMO partnerships to expand viral vector production and GMP-compliant facilities at unprecedented velocity, overcoming
More news about: Equity Insider
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
applications across multiple high-need genetic diseases. I am particularly excited by the potential of Dualase® genome editors to provide a durable, gene-level benefit for patients with diseases such as amyotrophic lateral sclerosis (ALS), where meaningful disease-modifying therapeutic options remain
More news about: Specific Biologics Inc.
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
applications across multiple high-need genetic diseases. I am particularly excited by the potential of Dualase® genome editors to provide a durable, gene-level benefit for patients with diseases such as amyotrophic lateral sclerosis (ALS), where meaningful disease-modifying therapeutic options remain
More news about: Specific Biologics Inc.
Dec 16, 2025, 09:06 ET Orsini Names Ashley Keller as Chief People Officer
thrive."About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Dec 16, 2025, 06:07 ET New Modeling Approach Sheds Light on Rare Gut Disease
realistic model of HSCR in mice. Instead of completely knocking out either gene, the researchers made different combinations of mice in which one or both genes were either still partially functional or in which just one copy of the gene was deleted.In the combination that best replicated the symptoms
More news about: NYU Langone Health System
Dec 15, 2025, 17:31 ET Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight
Gene Therapies for Cardiomyopathies Market SummaryThe market size for gene therapies for cardiomyopathies in the leading markets is expected to grow significantly by 2034.The United States accounted for the highest gene therapies for cardiomyopathies treatment
More news about: DelveInsight Business Research, LLP
Dec 15, 2025, 16:30 ET The Inner Circle acknowledges, Melvin Colón as a Pinnacle Professional Member Inner Circle of Excellence
market. Mr. Colón is a licensed chemist with a proven track record of success across the pharmaceutical, biotechnology, including cell and gene therapy, biosimilars, and medical device industries, including combination products. His expertise includes Quality Assurance Management, Quality Control,
More news about: The Inner Circle
Dec 15, 2025, 16:19 ET ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
disease-modifying therapy to people living with Alzheimer's around the world.""Erik Wallstroem, Global Head of Multiple Sclerosis, Neurology and Gene Therapy Development, Sanofi, commented: 'ADEL's innovative approach to targeting tau acetylation offers a promising and differentiated mechanism for
More news about: ADEL, Inc.
Dec 15, 2025, 14:58 ET Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
Cocktail assayThe VENTANA HER2 Dual ISH DNA Probe Cocktail assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene status. VENTANA HER2 Dual ISH helps identify breast cancer patients eligible for personalized treatment with HER2-targeted therapies. The VENTANA HER2
More news about: Roche
Dec 15, 2025, 13:00 ET Thatch and MyOme Launch First Genomics Solution in Thatch's Personalized Benefits Marketplace
positive ROI."What's AvailableThatch members can now access MyOme Proactive Health, which includes:Single-Gene Risk Insights: Identify clinically actionable variants that impact health and disease risk.Medication Response Insights (Pharmacogenomics):
More news about: MyOme, Inc
Dec 15, 2025, 11:01 ET UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE NAMES DISTINGUISHED SCIENTIST AND ACADEMIC LEADER GERALD M. WILSON, PHD, AS CHAIR OF THE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
42, Dr. Wilson's research has advanced understanding of the mechanisms of RNA-protein interactions; this includes their roles in post-transcriptional gene regulation and dysregulation of these processes in cancer and cardiovascular disease. His work has been funded by major grants from the National Institutes
More news about: University of Maryland Medical Center